Loading clinical trials...
Loading clinical trials...
This is an 80-week extension to a study to assess the safety and effectiveness of vildagliptin, an unapproved drug, compared to rosiglitazone in lowering overall blood glucose levels in people with type 2 diabetes who have not previously been treated with drug therapy to lower their blood sugar. The purpose of the extension study is to gather data on the long-term safety and effectiveness of vildagliptin in people with type 2 diabetes.
Age
18 - 80 years
Sex
ALL
Healthy Volunteers
No
Novartis Pharmaceuticals
East Hanover, New Jersey, United States
Investigative Centers, Germany
Start Date
November 1, 2004
Primary Completion Date
April 1, 2007
Completion Date
April 1, 2007
Last Updated
May 7, 2012
478
ACTUAL participants
vildagliptin
DRUG
Lead Sponsor
Novartis
NCT06959901
NCT06574035
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT06861062